A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.
Emmanuel S. Antonarakis
Consultant or Advisory Role - Dendreon
Research Funding - Dendreon
Adam S Kibel
Consultant or Advisory Role - Dendreon
George Adams
No relevant relationships to disclose
Lawrence Ivan Karsh
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Research Funding - The Urology Center of Colorado
Aymen Elfiky
No relevant relationships to disclose
Neal D. Shore
Employment or Leadership Position - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Medivation; Millennium
Nicholas J. Vogelzang
Consultant or Advisory Role - Amgen; ArQule; Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Celgene; Clinical Care Options; Cougar Biotechnology; Dendreon; Eisai; GE Healthcare; Genentech; GlaxoSmithKline; Johnson & Johnson; Lilly; Mannkind Corporation; Medscape; Novartis; Pfizer; Quintiles; Research to Practice; Sanofi ; Takeda; Veridex; Viamet Pharmaceuticals; Wilex
Honoraria - To be confirmed
Research Funding - Algeta; ArQule; Cougar Biotechnology; GlaxoSmithKline; Johnson & Johnson; Mannkind Corporation; Novartis; Pfizer; Takeda; Tokai; Veridex; Wilex
John M. Corman
No relevant relationships to disclose
Robert Claude Tyler
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Candice McCoy
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Yang Wang
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Charles G. Drake
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Janssen